STOCK TITAN

Harrow Strengthens Board Retention with Director Stock Awards

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
4

Rhea-AI Filing Summary

Director Adrienne L. Graves of Harrow received a new equity compensation award on June 20, 2025, as reported in this Form 4 filing. The transaction details include:

  • Awarded 7,339 Restricted Stock Units (RSUs) with $0 exercise price
  • RSUs will vest fully on the one-year anniversary of the grant date
  • Underlying shares cannot be delivered, transferred, or sold until termination of service

This grant appears to be part of the company's director compensation program, representing a standard compensatory award for board service. The filing was submitted by Andrew R. Boll as Attorney in Fact for the director on June 24, 2025, within the required reporting window. Ms. Graves holds these RSUs under direct ownership.

Positive

  • None.

Negative

  • None.
SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Graves Adrienne L

(Last) (First) (Middle)
C/O HARROW, INC.
1A BURTON HILLS BLVD, SUITE 200

(Street)
NASHVILLE TN 37215

(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
HARROW, INC. [ HROW ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
X Director 10% Owner
Officer (give title below) Other (specify below)
3. Date of Earliest Transaction (Month/Day/Year)
06/20/2025
4. If Amendment, Date of Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
RSU(1) $0 06/20/2025 A 7,339 (2) (2) Common Stock 7,339 $0 7,339 D
Explanation of Responses:
1. The Restricted Stock Units were received as a compensatory award for services rendered or to be rendered.
2. Award of Restricted Stock Units vests in full on the one-year anniversary following the date of grant. The shares underlying such Restricted Stock Units will not be delivered to the Reporting Person and may not be transferred or sold until the termination of service.
/s/ Andrew R. Boll as Attorney in Fact for Adrienne L. Graves 06/24/2025
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

How many Restricted Stock Units (RSUs) did HROW director Adrienne Graves receive on June 20, 2025?

According to the Form 4 filing, HROW director Adrienne L. Graves received 7,339 Restricted Stock Units (RSUs) on June 20, 2025 as a compensatory award for services rendered or to be rendered.

What is the vesting schedule for HROW director Graves' RSU grant?

The RSU award vests in full on the one-year anniversary following the date of grant (June 20, 2025). The underlying shares cannot be delivered, transferred, or sold until the termination of Graves' service with HROW.

What is the exercise price of the RSUs granted to HROW's director Adrienne Graves?

The Restricted Stock Units were granted with an exercise price of $0, as shown in Table II of the Form 4 filing under the 'Conversion or Exercise Price of Derivative Security' column.

Who filed this Form 4 for HROW and what is their role?

The Form 4 was filed by Andrew R. Boll as Attorney in Fact for Adrienne L. Graves, who serves as a Director of Harrow, Inc. (HROW). The form was signed on June 24, 2025.
Harrow Health Inc

NASDAQ:HROW

HROW Rankings

HROW Latest News

HROW Latest SEC Filings

HROW Stock Data

1.34B
31.07M
Drug Manufacturers - Specialty & Generic
Pharmaceutical Preparations
Link
United States
NASHVILLE